Insmed (NASDAQ:INSM) was downgraded by equities researchers at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on Wednesday, BidAskClub reports.
A number of other brokerages have also commented on INSM. Zacks Investment Research lowered shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 11th. HC Wainwright reaffirmed a “buy” rating and set a $52.00 price objective (up previously from $43.00) on shares of Insmed in a research report on Tuesday, April 9th. Finally, ValuEngine lowered shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $36.63.
Shares of INSM opened at $21.88 on Wednesday. The company’s 50-day moving average is $24.41. The firm has a market capitalization of $1.67 billion, a price-to-earnings ratio of -5.25 and a beta of 2.82. The company has a debt-to-equity ratio of 2.48, a current ratio of 4.82 and a quick ratio of 4.69. Insmed has a 52 week low of $11.31 and a 52 week high of $33.13.
Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.94) by ($0.02). The firm had revenue of $21.90 million for the quarter, compared to analyst estimates of $19.61 million. Equities research analysts predict that Insmed will post -3.58 earnings per share for the current year.
In related news, CEO William Lewis sold 400,000 shares of the stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $26.00, for a total value of $10,400,000.00. Following the completion of the transaction, the chief executive officer now owns 480,672 shares of the company’s stock, valued at $12,497,472. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 12,000 shares of the stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $23.24, for a total transaction of $278,880.00. Following the completion of the transaction, the insider now directly owns 36,350 shares of the company’s stock, valued at approximately $844,774. The disclosure for this sale can be found here. Corporate insiders own 4.95% of the company’s stock.
A number of large investors have recently bought and sold shares of INSM. Vivo Capital LLC acquired a new position in Insmed in the first quarter worth about $34,020,000. Norges Bank bought a new stake in Insmed during the fourth quarter worth about $9,955,000. Dimensional Fund Advisors LP grew its stake in Insmed by 260.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 782,614 shares of the biopharmaceutical company’s stock worth $10,268,000 after buying an additional 565,297 shares during the last quarter. Federated Investors Inc. PA bought a new stake in Insmed during the first quarter worth about $9,825,000. Finally, Emerald Mutual Fund Advisers Trust grew its stake in Insmed by 64.1% during the first quarter. Emerald Mutual Fund Advisers Trust now owns 841,119 shares of the biopharmaceutical company’s stock worth $24,451,000 after buying an additional 328,472 shares during the last quarter.
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Recommended Story: What is a stock split?
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.